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replicon cells. Apoptosis resistance was showed in CD44
knockdown HCV replicon and HCV-infected cells treated by
ActD.
Conclusion: These results suggested that there had an
intentive relationship between CD44, especially CD44v6
expression and anti-apoptosis in liver cancer tissues.
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Introduction: Cutaneous necrosis as a result of interferon
alfa is an infrequent complication with unknown
pathogenesis. We report a patient who developed local
cutaneous reactions at sites of injection after the
administration of interferon alfa-2b.
Case description: A 55-year-old woman with HCV-related
decompensated cirrhosis treated with every other day
subcutaneous injections of interferon alfa-2b (210MU) in
combination with ribavirin (800mg/d). Six months later,
a painful, erythematous, indurated plaque with centrally
ulcerated about 1.2 cm in diameter initially developed
on right abdomen. One week later, an additional ulcer
measuring 2 cm in maximum diameter, with peripheral
erythema and purulent contents, developed at the other
injection site on the left abdomen (Fig. 1). Results of skin
cultures were negative. A skin biopsy specimen showed
the presence of ulceration with ﬁbroplasia and vascular
proliferation consistent with a re-epithelializing ulceration.
The patient was advised to avoid injection on abdomen and
to intramuscular injection at triangular muscle with same
dose. The ulcers were treated with Mupirocin ointment,
healed in 1 months, and did not recur. Our case suggests
that the cutaneous lesions maybe healed without requiring
interruption or dose modiﬁcation of interferon after local
care and change of injection site.
Figure 1.
PP-140 Difference in liver function tests in patients
with chronic HCV-infection depend on some
predisposing factors
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Background: Aim of the study was comparison of liver
function tests, including ferritin, in patients with chronic
HCV-infection depends on patients age, gender, body mass
index (BMI), disease limitation, presence of anti bodies to
HBV, alcohol and drug abuse.
Methods: Evaluation of albumin, billirubin, ALT, AST, and
GGT was performed in 50 patients with chronic HCV-
infection by biochemical analyzer HumaStar 300. For
measurement of plasma ferritin level we used two-site
immunoenzymatic (“sandwich”) assay. Statistic analyses
were carried out with SPSS 11.0 and Excel.
Result: Level of AST was signiﬁcantly higher in HCV-infected
patients with obesity (BMI less than 25 56.8±8.0; BMI
25 30 59.3±11.9; BMI more than 30 79.4±20.1). GGT
was signiﬁcantly higher in HCV-infection with duration of
disease more than 10 years (less than 5 years 77.0±25.7;
5 10 years 88.7±9.7; more than 10 159.2±33.6).
Ferritinemia was higher in male in comparison with female
(326±38.4 vs. 108.2±44.7) and in long history of HCV-
infection (up to 5 years 198.8±45.9; 5 10 years
251.1±39.1; more than 10 546.5±80.8).
Conclusion: Signiﬁcant difference revealed in some liver
enzymes and ferritin depends on HCV-infected patients’
gender, BMI and limitation of disease.
Table 1. Liver function tests in patients with chronic HCV-infection
(n = 50)
Parameter Normal
range
Unit m SD SE Median Min Max 95% CI
Albumin 38 51 g/l 46.7 4.98 0.75 47 35 57.9 45.2 48.2
Bilirubin total <18.8 mmol/l 12.55 7.21 1.02 10.7 3.7 39.5 10.6 14.6
Bilirubin direct <4.3 mmol/l 3.09 2.36 0.33 2.4 0.6 12 2.44 3.75
AST <37 U/l 60.98 46.7 6.61 48 14 250 48.0 73.9
ALT <42 U/l 103.22 63.38 8.96 93 13 330 85.7 120.8
GGT 11 61 U/l 91.19 73.11 10.6 69.5 16 350 70.5 111.9
Ferritin 23.9 336.2 ng/dl 236.8 71.25 32.6 197.9 4.7 829.1 173.2 300.4
Table 2. Liver function tests in patients with chronic HCV-infection
depend on gender, age, disease limitation, BMI, HBV past-infection,
alcohol and drugs abuse
Criteria n Albumin Bilirubin ALT AST GGT Ferritin
Gender
Male
Female
42
8
46.6±0.7
45.9±1.6
12.8±1.2
12.0±1.4
110.6±9.8
75.5±24.2
65.2±8.0
54.5±14.1
104.7±12.0
59.5±26.5
326.0±38.4*
108.2±44.7
Age
<30
<31 40
41 50
>50
13
18
16
3
48.0±1.4
45.1±0.9
47.1±1.7
43.0±4.2
12.5±2.4
12.8±1.5
12.1±2.0
13.3±2.0
92.2±14.8
115.9±18.3
96.7±12.9
109.3±49.0
45.6±8.0
75.6±15.4*
53.8±7.0
78.0±26.6
76.7±14.1
96.8±20.1
99.6±20.9
71.0±8.0
157.3±32.1
357.4±50.9
293.7±90.7
90.6±18.6
BMI
<25
25 30
>30
21
21
8
47.1±1.2
45.7±1.2
48.1±1.8
14.4±2.0
10.4±1.0
13.5±2.0
106.0±15.9
90.0±13.3
117.9±15.5
56.8±8.0
59.3±11.9
79.4±20.1*
84.0±17.8
92.4±16.7
151.5±24.3
232.7±14.5
335.9±63.3
300.6±73.9
Disease limitation, years
<5
5 10
>10
13
26
10
48.2±1.4
45.4±0.7
47.6±2.2
13.0±2.6
12.8±1.5
12.4±0.7
78.2±11.2
113.6±14.0
126.8±19.7
41.3±7.2
70.4±11.0
77.5±16.6
77.0±25.7
88.7±9.7
159.2±33.6*
198.8±45.9
251.1±39.1
546.5±80.8*
HBcAb
Yes
No
16
32
46.5±1.3
46.1±0.8
9.6±0.9
14.4±1.5*
94.3±11.5
113.3±12.8
56.1±10.2
68.1±9.8
86.7±13.2
100.6±15.5
249.4±49.2
313.3±49.3
IVDU
Yes
No
23
26
46.1±0.9
46.7±1.0
12.3±1.8
13.2±1.2
109.4±13.6
104.6±12.6
54.9±7.2
72.3±11.9
85.3±11.0
110.1±18.5
326.2±47.6
262.2±52.2
Alcohol abuse
Ectb
HeT
17
32
45.0±1.0
47.2±0.9
10.4±1.1
14.1±1.5
107.7±11.6
106.4±12.7
57.0±7.3
67.9±10.3
107.2±16.4
94.1±15.1
340.2±71.7
264.8±40.5
Values are mean±SE.
*p-value <0.05.
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Objective: Study Serodynamics and viral clearance with
Reiferon Retard® in naïve Egyptian HCV patients mostly
genotype 4.
Methodology: 28 HCV patients randomly selected from
78 patients treated with Reiferon Retard®. 14 showed
sustained viral response and 14 were non responders and
relapsers. Assessment of serodynamics, viral load, viral
clearance and genotyping were performed on blood samples
collected at time of recruitment and at weeks 8, 12 and
